Evidence map›Paper›PMID 24819566›Full record

Trial reportPediatrics2014

Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.

Robin K Ohls, Beena D Kamath-Rayne, Robert D Christensen, Susan E Wiedmeier, Adam Rosenberg, Janell Fuller, Conra Backstrom Lacy, Mahshid Roohi, Diane K Lambert, Jill J Burnett and 4 more

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02745990 (Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants), which is not on this map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
25.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02745990 naunknown statusnot on this mapstarted 2016, after this paper: background citation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants

TypeinterventionalSponsorHuiqing SunRan2016 to 2022Enrolled440ConditionsDevelopmental DisabilitiesArmsRecombinant human erythropoietin, Normal saline
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. A prospective randomized pilot trial comparing weekly vs. biweekly Darbepoetin administration to preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Perinatal Neuroprotection in Preterm Birth.Geburtshilfe und Frauenheilkunde · 2025
    Article
  17. Review
  18. Observational
  19. Review
  20. Anemia, Iron Supplementation, and the Brain.Clinics in perinatology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Robin K OhlsDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico; rohls@salud.unm.edu.
Beena D Kamath-RayneCincinnati Children's Hospital, Cincinnati, Ohio;
Robert D ChristensenIntermountain Health Care, Salt Lake City, Utah;
Susan E WiedmeierDepartment of Pediatrics, University of Utah, Salt Lake City, Utah;
Adam RosenbergDepartment of Pediatrics, University of Colorado, Denver, Colorado;
Janell FullerDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico;
Conra Backstrom LacyDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico;
Mahshid RoohiDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico;
Diane K LambertIntermountain Health Care, Salt Lake City, Utah;
Jill J BurnettIntermountain Medical Center, Salt Lake City, Utah; and.
Barbara PrucklerDepartment of Pediatrics, University of Colorado, Denver, Colorado;
Hannah PecenyDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico;
Daniel C CannonDepartment of Medicine, University of New Mexico, Albuquerque, New Mexico.
Jean R LoweDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico;
University of New Mexico · USIntermountain Healthcare · USUniversity of Colorado Denver · USCincinnati Children's Hospital Medical Center · USIntermountain Medical Center · USUniversity of Utah · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
NCATS NIH HHS UL1 TR000041NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1 TR001082
6 · The paper itself

Abstract

backgroundWe previously reported decreased transfusions and donor exposures in preterm infants randomized to Darbepoetin (Darbe) or erythropoietin (Epo) compared with placebo. As these erythropoiesis-stimulating agents (ESAs) have shown promise as neuroprotective agents, we hypothesized improved neurodevelopmental outcomes at 18 to 22 months among infants randomized to receive ESAs.

methodsWe performed a randomized, masked, multicenter study comparing Darbe (10 μg/kg, 1×/week subcutaneously), Epo (400 U/kg, 3×/week subcutaneously), and placebo (sham dosing 3×/week) given through 35 weeks' postconceptual age, with transfusions administered according to a standardized protocol. Surviving infants were evaluated at 18 to 22 months' corrected age using the Bayley Scales of Infant Development III. The primary outcome was composite cognitive score. Assessments of object permanence, anthropometrics, cerebral palsy, vision, and hearing were performed.

resultsOf the original 102 infants (946 ± 196 g, 27.7 ± 1.8 weeks' gestation), 80 (29 Epo, 27 Darbe, 24 placebo) returned for follow-up. The 3 groups were comparable for age at testing, birth weight, and gestational age. After adjustment for gender, analysis of covariance revealed significantly higher cognitive scores among Darbe (96.2 ± 7.3; mean ± SD) and Epo recipients (97.9 ± 14.3) compared with placebo recipients (88.7 ± 13.5; P = .01 vs ESA recipients) as was object permanence (P = .05). No ESA recipients had cerebral palsy, compared with 5 in the placebo group (P < .001). No differences among groups were found in visual or hearing impairment.

conclusionsInfants randomized to receive ESAs had better cognitive outcomes, compared with placebo recipients, at 18 to 22 months. Darbe and Epo may prove beneficial in improving long-term cognitive outcomes of preterm infants.

Indexed as

Blood TransfusionCognitionConcept FormationDarbepoetin alfaDevelopmental DisabilitiesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleErythropoietinFemaleFollow-Up StudiesHumansInfantInfant, NewbornInfant, Premature, DiseasesInjections, SubcutaneousDarbepoetin alfaErythropoietincognitive outcomedarbepoetinerythropoietinprematurity

Identifiers

PMID24819566
PMCPMC4531269
OpenAlexW2110230188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.